A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying scintigraphy.
| Condition |
|---|
|
Gastrointestinal Diseases Stomach Diseases Gastroparesis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time |
- To demonstrate the correlation between the gastric residence time as determined by SmartPill GI Monitoring System and the gastric emptying time of a radiolabeled meal in both healthy subjects and patients with documented gastroparesis. [ Time Frame: 30 minute intervals up to 6 hours ] [ Designated as safety issue: No ]
- To demonstrate that the gastric residence time as determined by SmartPill GI Monitoring System can discriminate between healthy human subjects and patients with gastroparesis [ Time Frame: Continuous time measure until capsule elimination ] [ Designated as safety issue: No ]
- To characterize pressure patterns within the antrum and duodenum in healthy subjects and patients with documented gastroparesis [ Time Frame: Continuous time measure until capsule elimination ] [ Designated as safety issue: No ]
- To characterize total GI transit time in healthy subjects [ Time Frame: Continuous tume measure until capsule elimination ] [ Designated as safety issue: No ]
| Enrollment: | 148 |
| Study Start Date: | February 2005 |
| Study Completion Date: | October 2005 |
| Primary Completion Date: | October 2005 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Normal
healthy adult subjects with no history or current gastrointestinal disorders or conditions
|
|
Gastroparesis
Subjects with documented gastroparesis
|
Detailed Description:
Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management.
The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
patients with gastroparesis referred to a tertiary motility center
Inclusion Criteria:
Inclusion Criteria For Healthy Subjects:
- Healthy males and females between ages 18-65 years of age with no gastrointestinal disease as screened by the GI Disease Screening Questionnaire
- Average bowel movement frequency of at least one bowel movement within 48 hours
- Subjects with high probability for compliance and completion of the study
Inclusion Criteria For Subjects with Gastroparesis:
- Abnormal gastric emptying as defined by local standards and documented by nuclear medicine scintigraphy performed within the last two years.
- Males and females between ages 18-65 years of age.
- Average bowel movement frequency of at least one bowel movement within 72 hours
- Subjects with high probability for compliance and completion of the study
- Upper endoscopy or upper GI within last 3 years showing no evidence of gastric bezoar, stricture, or peptic ulcer.
Exclusion Criteria:
Exclusion Criteria For Healthy Subjects:
- Prior GI surgery
- Surgery within the past 3 months
- Diverticulitis
- Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
- Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
- Body mass index (BMI) > 35
- Allergies to components of the test meal including eggs, bread, and jam.
- Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
- Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
Exclusion Criteria For Subjects with Gastroparesis:
- History of gastric bezoar
- Severe dysphagia to solid food and pills
- Severe vomiting more than 1 time per day
- Diverticulitis
- Severe daily abdominal pain requiring medications for relief
- Severe weight loss, greater than 10 lbs over the preceding 2 months.
- Uncontrolled diabetes with a hemoglobin A1C greater than 10.
- Excessively delayed gastric emptying time: more than 90% of a standard egg meal retained after 2 hours.
- Previous gastro-esophageal surgery including vagotomy, fundoplication, gastric bypass, ulcer surgery.
- Prior GI surgery except for uncomplicated appendectomy and laparoscopic cholecystectomy
- Surgery within the past 3 months
- Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
- Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
- BMI > 35
- Allergies to components of the test meal including eggs, bread, and jam
- Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
Contacts and Locations| United States, Kansas | |
| Division of Gastroenterology and Hepatology at KUMC | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Kentucky | |
| University of Louisville Medical Center | |
| Louisville, Kentucky, United States, 40292 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Michigan | |
| University of Michigan Medical Center | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, New York | |
| VA Medical Center | |
| Buffalo, New York, United States, 14215 | |
| United States, North Carolina | |
| Wake Forest University Baptist Medical Center | |
| Winston-Salem, North Carolina, United States, 27157 | |
| United States, Pennsylvania | |
| Temple University Medical Center | |
| Philadelphia, Pennsylvania, United States, 19140 | |
| Study Director: | Jack Semler, PhD | SmartPill Corporation |
| Principal Investigator: | Braden Kuo, MD | Massachusetts General Hospital |
More Information
No publications provided
| Responsible Party: | John R. Semler/Chief Technology Officer, The SmartPill Corporation |
| ClinicalTrials.gov Identifier: | NCT00128284 History of Changes |
| Other Study ID Numbers: | 102204, NYSTAR C020118, NIH DK069614 |
| Study First Received: | August 8, 2005 |
| Last Updated: | May 21, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by The SmartPill Corporation:
|
gastroparesis Digestive Gastrointestinal Stomach Motility |
Non-Invasive Capsule GI Device Digestive System Diseases |
Additional relevant MeSH terms:
|
Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Gastroparesis |
Paralysis Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on May 22, 2013